NYSE:ZBH - Zimmer Biomet Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$112.92 +0.29 (+0.26 %)
(As of 07/17/2018 10:49 AM ET)
Previous Close$112.80
Today's Range$112.07 - $112.95
52-Week Range$104.28 - $133.49
Volume10,764 shs
Average Volume851,027 shs
Market Capitalization$23.35 billion
P/E Ratio13.99
Dividend Yield0.84%
Beta1.13
Zimmer Biomet logoZimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZBH
CUSIPN/A
Phone574-267-6131

Debt

Debt-to-Equity Ratio0.79
Current Ratio1.69
Quick Ratio1.07

Price-To-Earnings

Trailing P/E Ratio13.99
Forward P/E Ratio14.72
P/E Growth2.04

Sales & Book Value

Annual Sales$7.82 billion
Price / Sales2.93
Cash Flow$14.7031 per share
Price / Cash7.68
Book Value$57.96 per share
Price / Book1.95

Profitability

EPS (Most Recent Fiscal Year)$8.03
Net Income$1.81 billion
Net Margins21.81%
Return on Equity14.36%
Return on Assets6.02%

Miscellaneous

Employees18,200
Outstanding Shares203,270,000
Market Cap$23,353.80

The Truth About Cryptocurrencies

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Thursday, June 14th. Shareholders of record on Friday, June 29th will be given a dividend of $0.24 per share on Tuesday, July 31st. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date is Thursday, June 28th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) announced its quarterly earnings results on Thursday, April, 26th. The medical equipment provider reported $1.91 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.89 by $0.02. The medical equipment provider earned $2.02 billion during the quarter, compared to the consensus estimate of $1.98 billion. Zimmer Biomet had a net margin of 21.81% and a return on equity of 14.36%. Zimmer Biomet's quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.13 earnings per share. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Zimmer Biomet.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $7.60-$7.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.80. The company issued revenue guidance of $7.94-$8.09 billion, compared to the consensus revenue estimate of $7.96 billion.

What price target have analysts set for ZBH?

24 analysts have issued 1-year target prices for Zimmer Biomet's shares. Their predictions range from $96.00 to $168.00. On average, they anticipate Zimmer Biomet's stock price to reach $133.65 in the next year. This suggests a possible upside of 18.4% from the stock's current price. View Analyst Ratings for Zimmer Biomet.

What is the consensus analysts' recommendation for Zimmer Biomet?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 1 sell rating, 7 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:
  • 1. According to Zacks Investment Research, "In the past three months, Zimmer Biomet has been observed to underperform its industry. The year-over-year decline in earnings and revenues in the last reported quarter made investors jittery.  Declining sales at Knees, Hips and other segments at CER were a major disappointment. According to the company, slower pace of supply recovery and sales recapture related to major brands within the company’s Knee, Hip and S.E.T. segments marred the quarterly performance. Also, escalating costs and expenses impacted margins.  On the bright side, the company’s consistent efforts in product and renovation through research and development raise hopes. We are optimistic about synergies from the LDR buyout as well. We are also impressed by the strategic and financial goals which the combined entity expects to reach." (7/8/2018)
  • 2. Canaccord Genuity analysts commented, "We are updating our model to reflect Zimmer’s adoption of several previously disclosed new accounting standards (revenue recognition for customer contracts, reporting of pension costs, and hedging activities). The company adopted the changes effective January 1, 2018, and recently provided updated historical financials (for 2016 and 2017) to reflect a retrospective adoption of the new standards. While the new accounting policies have not resulted in any material changes to 2016 and 2017 historical results, we have nonetheless updated our model to reflect how the company will report moving forward. Additionally, we have also tweaked our forward estimates to incorporate a slightly more conservative revenue ramp in 2018/2019 and higher COGS and operating spend related to the quality/manufacturing remediation and sales channel incentives/ investments. Thus we maintain our HOLD rating and lower our price target to $121." (4/12/2018)
  • 3. Cantor Fitzgerald analysts commented, "ZBH received FDA clearance for its Persona cementless knee, earlier than we expected." (2/5/2018)

Who are some of Zimmer Biomet's key competitors?

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 51)
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 54)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 46)
  • Dr. Katarzyna Mazur-Hofsaess, Pres of Europe, Middle East & Africa (Age 54)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 56)

Has Zimmer Biomet been receiving favorable news coverage?

Headlines about ZBH stock have trended somewhat positive recently, according to Accern. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zimmer Biomet earned a media sentiment score of 0.10 on Accern's scale. They also gave headlines about the medical equipment provider an impact score of 46.62 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.09%), Fisher Asset Management LLC (0.05%), Kirr Marbach & Co. LLC IN (0.04%), Gulf International Bank UK Ltd (0.03%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Zimmer Biomet stock include Bryan C Hanson, Chad F Phipps, Daniel E Williamson, David A Jr Nolan, David C Dvorak, Katarzyna Mazur-Hofsaess, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which institutional investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Bank of Montreal Can, Fisher Asset Management LLC, Welch & Forbes LLC, Xact Kapitalforvaltning AB, Clinton Group Inc., Kirr Marbach & Co. LLC IN and Gateway Investment Advisers LLC. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.

Which institutional investors are buying Zimmer Biomet stock?

ZBH stock was purchased by a variety of institutional investors in the last quarter, including Bremer Trust National Association, FormulaFolio Investments LLC, Mitsubishi UFJ Asset Management UK Ltd., IFM Investors Pty Ltd, Gulf International Bank UK Ltd, Regent Investment Management LLC, State of Alaska Department of Revenue and Pennsylvania Trust Co. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $112.92.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $23.35 billion and generates $7.82 billion in revenue each year. The medical equipment provider earns $1.81 billion in net income (profit) each year or $8.03 on an earnings per share basis. Zimmer Biomet employs 18,200 workers across the globe.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]


MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  610 (Vote Outperform)
Underperform Votes:  488 (Vote Underperform)
Total Votes:  1,098
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.